{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"18","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields).","dispersionType":"95% Confidence Interval","groups":[{"description":"Adjuvant Chemotherapy:\n\nCapecitabine, 1500 mg/m\\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle; Gemcitabine hydrochloride, 1000 mg/m\\^2, IV, Days 1 \\& 8 of each cycle.\n\nChemoradiotherapy:\n\nCapecitabine, 1330 mg/m\\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT; Radiation (RT): 3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions; intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.","id":"OG000","title":"Adjuvant Chemotherapy + Chemoradiotherapy"}],"paramType":"NUMBER","populationDescription":"Eligible and analyzable patients that received protocol treatment.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from registration","title":"2-year Overall Local Relapse Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}